- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04064996
Effectiveness of Foot Exercise People With Type 2 Diabetes
Effectiveness of Foot Exercise Training on Patients With Type 2 Diabetes and Peripheral Neuropathy
Study Overview
Status
Conditions
Detailed Description
Purpose of our study investigation of the effects foot exercises in patients with type 2 diabetic and peripheral neuropathy.
Excepted results: Routine treatment + foot exercises pain, flexibility, edema, muscle strength, sensation, quality of life we believe that there will be good progress in peripheral neuropathy effects, Leeds assessment of neuropathic symptoms and signs(LANSS) results.
In this context, it is planned that patients randomly divided into 2 groups. Group 1 control group. Group 2 intervention group. Patients in the intervention group will be received standard treatment and performed foot exercises for three times a week 8 weeks. The patients will be evaluated by clinical measurements and scales based on patient notification at the 4th and 8th weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey
- Istanbul University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Having type 2 diabetes mellitus for 5 years
- HbA1c > among of between 6.5-10
- Having grade 0 or 1 phase of Wagner classification
- Diabetic neuropathy score ≥ 3
Exclusion Criteria:
- Not to know turkish
- Having hearing, visual and speaking problems
- Having (except diabetic neuropathy) other neurologic problems
- Having psychiatric and cognitive problems
- Having orthopedic, rheumatologic, cardiac, and pulmonary problems which stopping exercise
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group A
Routine rehabilitation program patient education
|
Patient education All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment. |
|
Experimental: Group B
Routine rehabilitation program + foot exercise training
|
In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks. All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain assessment with Algometry
Time Frame: Change from Baseline Pain at 8 weeks
|
An instrument for determining sensitivity to pain produced by pressure.
|
Change from Baseline Pain at 8 weeks
|
|
Pain assessment with The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale
Time Frame: Change from Baseline Pain at 8 weeks
|
The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) Pain Scale evaluates sensory dysfunction and whether the pain is caused by neuropathic mechanisms or not.
The LANSS comprises a 5-item questionnaire regarding pain symptoms and two items for clinical signs involving self-administered sensory tests for the presence of allodynia and decreased sensation to pinprick.
Responses to each item are binary (yes or no) and each item is weighted differently depending on the odds ratio of a positive response to each item to predict that the pain is primarily neuropathic.
The possible scores range from 0 to 24, with a score of 12 or greater considered to be suggestive of neuropathic pain
|
Change from Baseline Pain at 8 weeks
|
|
Pain assessment With Visual Analog Scale
Time Frame: Change from Baseline Pain at 8 weeks
|
Participants are asked to mark the point where they feel their pain on a 10 centimeter (cm) horizontal line.
0-no pain, 10-unbearable pain.
Night, activity and pain conditions are evaluated separately at rest.
|
Change from Baseline Pain at 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle Strength with Hand held dynamometer
Time Frame: 1th day, 8th week
|
The Hand-Held Dynamometer (formerly known as the Manual Muscle Tester) is an ergonomic hand-held device for objectively quantifying muscle strength.
|
1th day, 8th week
|
|
Range Of Motion with goniometer
Time Frame: 1th day, 8th week
|
A goniometer is a device used in physical therapy to measure the range of motion around a joint in the body.
|
1th day, 8th week
|
|
Baseline Tactile Semmes-Weinstein Monofilament
Time Frame: 1th day, 8th week
|
Baseline Tactile Semmes-Weinstein Monofilaments are designed to measure cutaneous sensory perception threshold of a patient.
|
1th day, 8th week
|
|
Edema measurement of tape
Time Frame: 1th day, 8th week
|
Use a measuring tape to measure the circumference of your leg.
Write down its circumference and repeat daily for a few days, using the same area on your the leg.
|
1th day, 8th week
|
|
Evaluation of functional capacity with 6 minutes walking test
Time Frame: 1th day, 8th week
|
The 6-minute walk test is one of the functional exercise capacity assessment tests.
In this test, participants are asked to walk as long as possible within 6 minutes in a 30 meter (m) corridor.
When they feel fatigue or pain, they are advised to stop and rest when they feel ready to walk.
At the end of 6 minutes, the total distance of the patients walking is recorded.
Heart rates, systolic and diastolic blood pressures, O2 saturation, perceived fatigue and dyspnea levels are recorded before and after the test.
|
1th day, 8th week
|
|
Two Point Discrimation Test
Time Frame: 1th day, 8th week
|
The two-point discrimination test is used to assess if the patient is able to identify two close points on a small area of skin, and how fine the ability to discriminate this are.
It is a measure of tactile agnosia, or the inability to recognize these two points despite intact cutaneous sensation and proprioception.
|
1th day, 8th week
|
|
The Foot and Ankle Ability Measure
Time Frame: 1th day, 8th week
|
The Foot and Ankle Ability Measure (FAAM) is a self-report outcome instrument developed to assess physical function for individuals with foot and ankle related impairments.
|
1th day, 8th week
|
|
HbA1c
Time Frame: 1 th day, 8th week
|
HbA1c (A1c or glycosylated hemoglobin) is widely used as the most important marker for routine monitoring of long term glycemic status in patients with diabetes.
|
1 th day, 8th week
|
|
Serum creatinine
Time Frame: 1 th day, 8th week
|
The kidneys are responsible for keeping the level of creatinine in the blood within a normal range.
The typical reference range for serum creatinine is 60 to 110 micromoles per liter (μmol/L) (0.7 to 1.2 milligrams per deciliter (mg/dL)) for men and 45 to 90 μmol/L (0.5 to 1.0 mg/dL) for women.
|
1 th day, 8th week
|
|
Albumin levels
Time Frame: 1 th day, 8th week
|
A normal albumin range is 3.4 to 5.4 g/dL.
If you have a lower albumin level, you may have malnutrition.
It can also mean that you have liver disease or an inflammatory disease.
Higher albumin levels may be caused by acute infections, burns, and stress from surgery or a heart attack.
|
1 th day, 8th week
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Evrim Koçarslan, Researcher
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 199292
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Canterbury Christ Church UniversityBarts & The London NHS Trust; Betsi Cadwaladr University Health BoardRecruitingType 1 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM)United Kingdom
Clinical Trials on Routine rehabilitation program patient education
-
University of the State of Santa CatarinaCompleted
-
Chinese University of Hong KongUniversity of SydneyCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Ege UniversityThe Scientific and Technological Research Council of TurkeyCompleted
-
Iran University of Medical SciencesRecruiting
-
Emine ŞAHİNRecruitingShortness of BreathTurkey (Türkiye)
-
Wen-Shao LinNational Taipei University of Nursing and Health Sciences; Cheng Hsin Rehabilitation...Active, not recruitingScleroderma, SystemicTaiwan
-
Karolinska InstitutetCompletedFunctional Gastrointestinal DisordersSweden
-
National Taiwan University HospitalCompleted
-
Hospices Civils de LyonCompletedHypermobility Type Ehlers-Danlos SyndromeFrance